Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

NCT02160990 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication exenatide affects how quickly food leaves the stomach in adults with obesity.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 20 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2014-06 · est. completion 2015-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02160990 ↗

Description as written by the study sponsor.

The overall goal of this study was to determine the effect of exenatide on gastric emptying, satiety and satiation in obese participants. The hypothesis in this study was that exenatide retards gastric emptying in obese patients with baseline accelerated gastric emptying.

Treatments tested

Exenatide also known as Byetta Drug

5 mcg exenatide subcutaneously twice daily for 30 days
Placebo Drug

placebo subcutaneously twice daily for 30 days

Main thing measured	Gastric Emptying Half-time (T 1/2) of Solids
Sponsor	Mayo Clinic
Conditions studied	Obesity
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02160990 ↗